PRESS RELEASE

PIERREL IN NORTH AMERICA
GOCCLES® APP LAUNCHED

Capua, 22 February, 2022 - Pierrel Pharma Srl ("Pierrel Pharma" or the "Company") - a wholly owned subsidiary of Pierrel SpA and devoted to the development, registration and licensing of new drugs and medical devices - announces the launch of the GOCCLES® App, suitable for iOS and Android, in support of its oral cancer screening device GOCCLES®.

The GOCCLES® device consists of eyewear fitted with patented optical filters that when used with a common curing light allows an autofluorescence visualization of the oral cavity to screen for oral abnormalities such as dysplastic or anaplastic lesions.

The GOCCLES® App will provide dental professionals with a guided inspection of the oral cavity using an expansive library of reference images representing the most common oral lesions. In addition, on-line clinical support will be available through the App from professionals to help identify suspicious lesions in case of uncertainties. An anamnestic file for each patient can be created with pictures taken with or without the GOCCLES® smartphone camera clip, which is included in the GOCCLES® kit. The app can be downloaded from the Apple Store or Goggles Play.

Says Fabio Velotti, CEO of the Company: “This app will respond to a clinical need by guiding dental professionals, using the GOCCLES® eyewear, to further distinguish a suspicious oral lesion.”
Pierrel S.p.A. and Pierrel Pharma Ltd.

**Pierrel S.p.A.** specializes in the production of pharmaceutical specialties (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division). The Pierrel Group - listed on the MTA market organized and managed by Borsa Italiana - boasts over 60 years of experience in the pharmaceutical sector and is one of the leading European producers of local and dental anesthetics. Pierrel owns a production plant in Capua, near Naples (Italy), which has received the authorization from the EMA (“European Medicines Agency”) and the FDA (“Food and Drug Administration”) for the production in asepsis of drugs for injectable use. The subsidiary Pierrel Pharma S.r.l. has registered and distributes Orabloc® dental anesthetics in Canada, USA, Russia and Europe. The registered office of Pierrel S.p.A. is in Capua (CE), Italy.

Pierrel Pharma is the company, within the Pierrel group, responsible for registration and commercial development of Pierrel branded pharmaceutical products, anesthetics for dental use, such as Articaine, Lidocaine and Mepivacaine. Pierrel successfully launched its Articaine in the U.S. in 2011, the very first aseptically manufactured articaine ever introduced in the U.S, under the registered trademark ‘Orabloc®’. Pierrel Articaine is also marketed throughout the world in more than 20 countries. Pierrel Pharma also markets worldwide GOCICLES®, an innovative and easy to use oral cancer screening device which bases its technology on the detection of the autofluorescence of the oral mucosa when irradiated by a curing light.

For more information visit: [www.goccles.com](http://www.goccles.com) – [www.orabloc.com](http://www.orabloc.com)/orabloc-needlestick-safety-system – [www.pierrel.it](http://www.pierrel.it)

**Pierrel Pharma srl**

Fabio Velotti
Email: orabloc@pierrelgroup.com
www.goccles.com
www.orabloc.com
www.orabloc.com/orabloc-needlestick-safety-system/